Celgene and the scientist who championed fedratinib's rise from Sanofi's R&D graveyard win FDA OK
Six years after Sanofi gave it up for dead, the FDA has approved the myelofibrosis drug fedratinib, now owned by Celgene.
The drug will be sold as Inrebic, and will soon land in the portfolio at Bristol-Myers Squibb, which is finalizing a deal to acquire Celgene.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 73,300+ biopharma pros reading Endpoints daily — and it's free.